Translational Basic and Clinical Research Training in Rheumatology

风湿病学转化基础和临床研究培训

• 批准号: 10411569
• 负责人: Jill P Buyon
• 金额: $ 31.08万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-05-01 至 2027-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10411569
• 关键词: Basic Science; Clinical Research; Research Training; Rheumatology

The Translational Basic and Clinical Research Training in Rheumatology, led in its first cycle by NYU Rheumatology Division Director Dr. Jill Buyon, will in its second cycle be co-directed under an mPI arrangement. Adding to Dr. Buyon’s extensive translational experience in SLE and autoimmunity, Dr. Jose Scher provides complementary expertise in inflammatory arthridities, including psoriatic and rheumatoid arthritis. Our mission remains clear: to support trainees through an extended period of development; to leverage emerging research opportunities to engage and excite physicians; and to bring clinical context to the pre-doctoral bench. Accordingly, our program extends traditional ACGME training and again proposes support for 2-yr training of 3 fellowship graduates, plus 1 predoctoral MD/PhD candidate to establish an early pipeline to rheumatology. In our first 4 years: a) 3 rheumatology graduates completed training (2 advancing to NYU faculty positions with external multi-year grants and publications, and 1 garnering a leadership role in industry based on accomplishments; b) 2 pre-doctoral MD/PhD trainees successfully defended a PhD thesis with publications; c) 3 fellows and 1 MD/PhD candidate (URM) remain in training; d) 2 NYU junior faculty advanced as Primary Mentors with new R01 awards e) Dr. Timothy Niewold, expertise in type I Interferon, was recruited; f) new NIH research programs were added, including a P50 in preclinical and clinical lupus, and renal and skin transcriptomics in SLE as part of AMP; g) clinical/basic research programs addressing COVID-19 and rheumatic diseases spawned during the pandemic engaged the pivot of trainees and faculty as they assumed unprecedented patient responsibilities. At the core of the present proposal is interdisciplinary training along 2 methodologically distinct research tracks, each bearing the prefix “translational” –basic or clinical – to emphasize the common purpose of all healthcare investigators. An Early Scientist Pathway is again offered to MD/PhD candidates recruited through our school’s MD/PhD and graduate programs, including the Immunology/Inflammation program and the newly established Translational Research Immunology Center (TrIC). Training tracks are grounded in core disease clusters reflecting faculty expertise and nationally recognized leadership: 1) lupus and diseases of systemic autoimmunity; 2) inflammatory and autoimmune arthritis; and 3) degenerative and metabolic bone disease. Each incorporates common and customized didactics; individualized research training experiences with teams of Primary, Associate, and Methodological Mentors to integrate science and medicine; a hand-picked Advisory Mentoring Committee for each trainee; and planning to support post-T32 faculty advancement. Programmatic success is evaluated though Executive Committee meetings and an Annual Showcase Retreat. Strong institutional commitment supports infrastructure and additional funding. The twice-renewed Clinical/Translational Science Institute provides extensive resources. This T32 program represents the ongoing trajectory of our capacity-building and scientific dedication, affirming and expanding commitment to advanced training in the rheumatic diseases.

风湿病学的转化基本和临床研究培训，在纽约大学的第一个周期中领导 风湿病学部主任吉尔·布隆（Jill Buyon）博士将根据MPI安排共同指导其第二个周期。 除了Buyon博士在SLE和自身免疫中的广泛翻译经验外，Jose Scher博士提供了 炎症性关节性的互补专业知识，包括银屑病和类风湿关节炎。我们的使命 仍然很清楚：通过长时间的发展支持培训；利用新兴研究 参与和令人兴奋的医生的机会；并将临床环境带到博士前的长凳上。 根据我们的计划扩展了传统的ACGME培训，并再次提出支持2年培训3 奖学金的毕业生，以及1名候选人MD/PHD候选人，以建立风湿病的早期管道。在我们的 前4年：a）3个风湿病学毕业生完成了培训（2个前往纽约大学教师职位 多年的赠款和出版物，以及1个基于成就在行业中发挥领导作用； b） 2博士前的MD/PHD学员成功地定义了一篇博士学位论文； c）3名研究员和1个MD/PHD 候选人（URM）仍在培训中； D）2 NYU初级教师担任新R01奖的主要导师 e）招募了I型干扰素的专业知识Timothy Niewold博士； f）添加了新的NIH研究计划， 包括临床前和临床狼疮的P50，以及SLE的肾脏和皮肤转录组学作为AMP的一部分； g） 临床/基础研究计划，涉及大流行期间产卵的Covid-19和风湿性疾病 当他们承担前所未有的患者责任时，参与了学员和教职员工的枢纽。核心 目前的建议是沿2个方法论上不同的研究轨道的跨学科培训，每个研究轨道都有 前缀“翻译”（基本或临床），以强调所有医疗保健研究者的共同目的。早 科学家途径再次提供给通过我们学校的MD/PhD招募的MD/PHD候选人 计划，包括免疫学/炎症计划和新成立的转化研究 免疫学中心（TRIC）。培训轨道基于反映教师专业知识和 全国认可的领导力：1）狼疮和系统性自身免疫的疾病； 2）炎症和 自身免疫性关节炎； 3）退化性和代谢骨病。每个合并共同 定制的教学法；与小学，同事团队的个性化研究培训经验 融合科学和医学的方法论导师；每个人都有一个精心挑选的咨询指导委员会 学员;并计划支持T32后的教师进步。虽然评估了程序化成功 执行委员会会议和年度展示务会。强大的机构承诺支持 基础设施和额外资金。两次更新的临床/转化科学学院提供了广泛的 资源。该T32计划代表了我们能力建设和科学奉献的持续轨迹， 确认对风湿性疾病高级培训的承诺。